论文部分内容阅读
目的:观察中药微调三号(WD-3)抗大肠癌肝转移的作用,并探讨其可能的作用机制。方法:将96只BALB/c小鼠分为两大组,两组均建立大肠癌肝转移模型并随机分为6组:模型组,西药组,中药低、中、高剂量组,中西药组。分组治疗4周,分别从小鼠生存时间、移植瘤和转移瘤的大体形态学、组织病理学及血清癌胚抗原(CEA)水平来观察WD-3的疗效。结果:西药组及中西药组与其他各组比较,小鼠生存时间延长,肝脏转移癌结节减少、癌重减轻(P<0.05),其中中西药组低于西药组(P<0.05)。西药组及中西药组与其他各组比较,CEA含量明显降低(P<0.05)。结论:WD-3联合化疗可以抑制模型动物肝脏转移瘤的生长。
OBJECTIVE: To observe the anti-tumor effect of WD-3 on liver metastasis of colorectal cancer and to explore its possible mechanism. Methods: Ninety-six BALB / c mice were divided into two groups. Liver metastasis model was established in both groups and randomly divided into 6 groups: model group, western medicine group, low, medium and high dose traditional Chinese medicine group, . The therapeutic effect of WD-3 was observed after 4 weeks of treatment. The survival time, the general morphology of tumor xenografts and metastases, histopathology and serum carcinoembryonic antigen (CEA) levels were observed. Results: Compared with other groups, western medicine group and western medicine group prolonged survival time, reduced nodules of liver metastasis and decreased cancer weight (P <0.05), and Western medicine group was lower than Western medicine group (P <0.05). Western medicine group and Western medicine group compared with other groups, CEA content was significantly lower (P <0.05). Conclusion: WD-3 combined with chemotherapy can inhibit the growth of liver metastases in model animals.